Bringing the very best science and medicine to our best equine friends

NEWS

Kindred Biosciences Announces Fourth Quarter and Year End 2013 Financial Results

San Francisco, CA. (March 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the fourth quarter and year ended December 31, 2013. KindredBio will host a webcast and conference call at 1:30 p.m. (PT) this afternoon to review its corporate progress and financial results.

Continue Reading

Kindred Bio Announces Exercise of Over-Allotment Option

SAN FRANCISCO, California. (December 13, 2013) – Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the underwriters of its initial public offering exercised in full their option to purchase up to 1,125,000 additional shares of its common stock at the initial public offering price of $7.00 per share.

Continue Reading

KindredBio Announces Pricing of Initial Public Offering

SAN FRANCISCO, CA, Dec 11, 2013 (Marketwired via COMTEX) — Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at an initial public offering price of $7.00 per share for a total offering amount of $52,500,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio. KindredBio has granted to the underwriters a 30-day option to purchase an additional 1,125,000 shares of its common stock at the initial public offering price. All of the …

Continue Reading

KindredBio Announces Launch of Initial Public Offering

SAN FRANCISCO, California. (December 2, 2013) – Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, announced the commencement of its initial public offering of 5,750,000 shares of its common stock, at an anticipated initial public offering price between $6.00 and $8.00 per share. KindredBio also expects to grant the underwriters a 30-day option to purchase up to an additional 862,500 shares of KindredBio’s common stock to cover over-allotments, if any. All shares of the common stock to be sold in the offering will be offered by the Company. KindredBio has applied to …

Continue Reading

KindredBio Announces Appointment of Stephen Sundlof, Former Director of FDA’s CVM, as Senior Vice President of Regulatory Affairs

SAN FRANCISCO, California. (August 22, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Stephen Sundlof, DVM, PhD, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as its Senior Vice President of Regulatory Affairs.

Continue Reading

KindredBio Announces Protocol Concurrences from the FDA on Pivotal Studies

FDA issues the equivalent of a Special Protocol Assessment on KIND-001 and KIND-002 Pivotal Studies. SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has received concurrences from the Center for Veterinary Medicine of the U.S. Food and Drug Administration (FDA) on its protocols for two pivotal (Phase III) field studies for KIND-001 and KIND-002. A protocol concurrence, similar to a Special Protocol Assessment for a human study, is a written commitment from the FDA that it is in agreement with the design, execution, and the analysis proposed in the protocol.

Continue Reading

KindredBio Announces the Filing of an INAD for Laminitis in Horses

KIND-005 is expected to be a major new therapy for the treatment of laminitis in horses. SAN FRANCISCO, California. (March 26, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-005. KIND-005 inhibits a biological pathway that plays a critical role in the pathogenesis of equine laminitis.

Continue Reading